GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Beam Therapeutics
BEAM
$2.11B
| $43.1K | ﹤0.01% |
+1,739
| New | +$43.1K |
|
402
Apogee Therapeutics
APGE
$2.26B
| $42.8K | ﹤0.01% |
+945
| New | +$42.8K |
|
403
Ligand Pharmaceuticals
LGND
$3.25B
| $42.5K | ﹤0.01% |
+397
| New | +$42.5K |
|
404
InvenTrust Properties
IVT
$2.33B
| $42.2K | ﹤0.01% |
+1,402
| New | +$42.2K |
|
405
Supernus Pharmaceuticals
SUPN
$2.58B
| $41.9K | ﹤0.01% |
+1,159
| New | +$41.9K |
|
406
Mirum Pharmaceuticals
MIRM
$3.82B
| $41.7K | ﹤0.01% |
+1,008
| New | +$41.7K |
|
407
Sunstone Hotel Investors
SHO
$1.81B
| $41.6K | ﹤0.01% |
+3,510
| New | +$41.6K |
|
408
Harmony Biosciences
HRMY
$2.07B
| $41.2K | ﹤0.01% |
+1,198
| New | +$41.2K |
|
409
Medical Properties Trust
MPW
$2.77B
| $40.9K | ﹤0.01% |
+10,361
| New | +$40.9K |
|
410
Akero Therapeutics
AKRO
$3.58B
| $40.8K | ﹤0.01% |
+1,466
| New | +$40.8K |
|
411
CG Oncology
CGON
$2.52B
| $40.7K | ﹤0.01% |
+1,420
| New | +$40.7K |
|
|
ROIC
412
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $40.2K | ﹤0.01% |
+2,316
| New | +$40.2K |
|
|
CURB
413
Curbline Properties Corp.
CURB
$2.41B
| $39.8K | ﹤0.01% |
+1,715
| New | +$39.8K |
|
414
Disc Medicine
IRON
$2.11B
| $39.6K | ﹤0.01% |
+625
| New | +$39.6K |
|
415
Wave Life Sciences
WVE
$1.32B
| $39.6K | ﹤0.01% |
+3,202
| New | +$39.6K |
|
416
Agios Pharmaceuticals
AGIO
$2.09B
| $39.3K | ﹤0.01% |
+1,197
| New | +$39.3K |
|
417
Amphastar Pharmaceuticals
AMPH
$1.37B
| $37.5K | ﹤0.01% |
+1,010
| New | +$37.5K |
|
418
ImmunityBio
IBRX
$2.27B
| $37.5K | ﹤0.01% |
+14,632
| New | +$37.5K |
|
419
MannKind Corp
MNKD
$1.7B
| $37.2K | ﹤0.01% |
+5,791
| New | +$37.2K |
|
420
Neumora Therapeutics
NMRA
$272M
| $36K | ﹤0.01% |
+3,392
| New | +$36K |
|
421
Indivior
INDV
$3.12B
| $35.6K | ﹤0.01% |
+2,862
| New | +$35.6K |
|
422
Dynavax Technologies
DVAX
$1.18B
| $35.2K | ﹤0.01% |
+2,760
| New | +$35.2K |
|
423
Fortrea Holdings
FTRE
$1.06B
| $35.1K | ﹤0.01% |
+1,883
| New | +$35.1K |
|
424
Innovative Industrial Properties
IIPR
$1.61B
| $34.3K | ﹤0.01% |
+515
| New | +$34.3K |
|
425
Arcutis Biotherapeutics
ARQT
$2.06B
| $34.2K | ﹤0.01% |
+2,458
| New | +$34.2K |
|